Company intelligence / Profile preview
Saiba Biotech
Pfäffikon, Schwyz, Switzerland
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
Saiba Biotech has developed VLP-based vaccines targeting chronic and infectious diseases; its SARS-CoV-2 vaccine showed preclinical proof of concept as of 2020 and the platform is being used for other chronic/infectious indications targeting strong immunogenicity especially in older adults
- Therapeutic areas
- Infectious DiseasesNeurologyDermatology
- Modalities
- VaccineVirus-like particle
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
AGC Biologics (CDMO partner for COVID-19 vaccine)Allergy Therapeutics (licensed VLP technology)Evax (licensing deal)HypoPet (licensing deal)
Beyond the preview
Go deeper on Saiba Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saiba Biotech.